PYPD$5.52+1.85%
PolyPid Ltd.
Sector: Surgical & Medical Instruments & ApparatusIndustry: BiotechnologyCountry: ILExchange: Nasdaq
Mkt Cap:$115.17M
Float & O/S:
Inst Own:
DilutionScan read 56 of PolyPid Ltd.'s SEC filings and found 8 warrant series, 2 ATM programs and 5 shelf registrations on file for PYPD. The latest dilution event on file is ATM sales on Jul 31, 2026. Analysis updated Oct 6, 2026.
Signal8 Summary
PYPD
Pre-revenue biotech nearing FDA decision
Snapshot
PolyPid is a pre-revenue biotech with no product sales yet, losing $34.2M in FY 2025 on top of similar losses the two years before. It holds only $12.9M in cash, but recent milestone payments from a new partner reportedly push its funding into 2028.
What's Happening Right Now
- : On Aug 15, 2026, the FDA accepted PolyPid's NDA for D-PLEX100 with Priority Review, setting a PDUFA date of Nov 28, 2026 (about a quarter earlier than expected) and triggering a $15M milestone payment from partner Azurity.
- : On Aug 12, 2026, PolyPid reported a Q2 net loss of $7.8M ($0.35/share) and said the recent Azurity milestone payments extend its cash runway into 2028.
- : On Jul 21, 2026, PolyPid signed an exclusive deal with Azurity Pharmaceuticals to commercialize D-PLEX100 in the U.S. and Canada, worth $15M upfront plus up to $300M in milestones and royalties, with a targeted 2027 launch.
